Insider Deck research · News

NAMS stock news · NewAmsterdam Pharma Company N.V.

Latest NewAmsterdam Pharma Company N.V. (NAMS) stock news, headlines, and research context on Insider Deck. Market cap $3.2B.

News desk

NewAmsterdam Pharma Company N.V. wire

Read the briefing on Insider Deck — headline, teaser, and desk context stay here. Publisher sites remain optional for the full longform.

6 on the wireUpdated within the hour

MarketBeat·Wed, Aug 5, 5:04 PM

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch. Chief Executive Officer Michael Davidson said the

Insider Deck desk note

Last$27.42
Day-0.47%
SymbolNAMS

Cross-check the tape against filings and ownership — the headline is the spark; the desk is the research.

Company KPIsShareholdersBuys vs Sells
Continue on MarketBeat

Frequently asked questions

What is the latest news on NAMS?

The NAMS news desk aggregates recent headlines with research context for NewAmsterdam Pharma Company N.V..

Where can I research NAMS on Insider Deck?

NewAmsterdam Pharma Company N.V. (NAMS) research covers KPIs, earnings, fundamentals, institutional ownership, 13F flow, news, and DCF valuation.